Top

Published in:

01-03-2013 | Medical Progress in the Journal of Neurology

Multiple sclerosis imaging: recent advances

Authors: Maria A. Rocca, Roberta Messina, Massimo Filippi

Published in: Journal of Neurology | Issue 3/2013

Abstract

In this review, we summarize advances in knowledge derived from the application of magnetic resonance imaging (MRI)-based techniques to patients with multiple sclerosis (MS) published in the Journal of Neurology over the past year. We highlight the pivotal role played by conventional MRI techniques for a correct and early diagnosis of this condition and the exclusion of alternative disorders. Advanced MR methods have contributed to demonstrating how damage to selected brain structures is related to disease clinical manifestations, thus contributing to overcome the well-known “clinical-radiological” paradox of MS, and ameliorating the understanding of the mechanisms underlying the accumulation of irreversible disability. Finally, we discuss the use of MRI to assess treatment efficacy and optimize therapeutic approaches in this condition.

The Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732CrossRef

Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64:1157–1161PubMedCrossRef

Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ (1997) Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 244:76–84PubMedCrossRef

Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer MG, Weinstock-Guttman B, Benedict RH (2012) Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 259:139–146PubMedCrossRef

Bot JC, Barkhof F (2009) Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. Neuroimaging Clin N Am 19:81–99PubMedCrossRef

Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144–1150PubMedCrossRef

Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, Miller DH, Montalban X, Simon JH, Polman C, Filippi M (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”. Lancet Neurol 5:841–852PubMedCrossRef

Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151PubMedCrossRef

Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, Yang M, Hulme A, O’Connor P, Miller DH (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251:407–413PubMedCrossRef

10.

Eckstein C, Saidha S, Levy M (2012) A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 259:801–816PubMedCrossRef

11.

Filippi M, Agosta F, Spinelli EG, Rocca MA (2012) Imaging resting state brain function in multiple sclerosis. J Neurol. doi:10.1007/s00415-012-6695-z

12.

Filippi M, Horsfield MA, Ader HJ, Barkhof F, Bruzzi P, Evans A, Frank JA, Grossman RI, McFarland HF, Molyneux P, Paty DW, Simon J, Tofts PS, Wolinsky JS, Miller DH (1998) Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43:499–506PubMedCrossRef

13.

Filippi M, Rocca MA, Camesasca F, Cook S, O’Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V (2011) Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 76:1222–1228PubMedCrossRef

14.

Filippi M, Rocca MA, Colombo B, Falini A, Codella M, Scotti G, Comi G (2002) Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15:559–567PubMedCrossRef

15.

Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68:1514–1520PubMedCrossRef

16.

Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 57:731–733PubMedCrossRef

17.

Goodin DS (2006) Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 59:597–605PubMedCrossRef

18.

Hackmack K, Weygandt M, Wuerfel J, Pfueller CF, Bellmann-Strobl J, Paul F, Haynes JD (2012) Can we overcome the ‘clinico-radiological paradox’ in multiple sclerosis? J Neurol 259:2151–2160PubMedCrossRef

19.

Harrison DM, Shiee N, Bazin PL, Newsome SD, Ratchford JN, Pham D, Calabresi PA, Reich DS (2012) Tract-specific quantitative MRI better correlates with disability than conventional MRI in multiple sclerosis. J Neurol. doi:10.1007/s00415-012-6638-8

20.

Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kumpfel T (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665–1669PubMedCrossRef

21.

Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O’Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260PubMedCrossRef

22.

Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hunter K, Tozer DJ, Miller DH, Kapoor R (2012) Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol 259:237–245PubMedCrossRef

23.

Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hunter K, Tozer DJ, Miller DH, Kapoor R (2012) Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol 259:505–514PubMedCrossRef

24.

Hellwig K, Gold R (2011) Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 258:1920–1928PubMedCrossRef

25.

Hickman SJ, Dalton CM, Miller DH, Plant GT (2002) Management of acute optic neuritis. Lancet 360:1953–1962PubMedCrossRef

26.

Horwitz H, Degn M, Modvig S, Larsson HB, Wanscher B, Frederiksen JL (2012) CSF abnormalities can be predicted by VEP and MRI pathology in the examination of optic neuritis. J Neurol 259:2616–2620PubMedCrossRef

27.

Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9:681–688PubMedCrossRef

28.

Kleinfeld K, Mobley B, Hedera P, Wegner A, Sriram S, Pawate S (2012) Adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia: report of five cases and a new mutation. J Neurol. doi:10.1007/s00415-012-6680-6

29.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedCrossRef

30.

Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081–1087PubMedCrossRef

31.

Melin A, Outteryck O, Collongues N, Zephir H, Fleury MC, Blanc F, Lacour A, Ongagna JC, Berteloot AS, Vermersch P, de Seze J (2012) Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol 259:1215–1221PubMedCrossRef

32.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14:1157–1174PubMedCrossRef

33.

Nociti V, Batocchi AP, Luigetti M, Conte A, Lorusso VS, Roiati S, Tartaglione T, Del Grande A, Sabatelli M (2011) Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else? J Neurol 258:1965–1970PubMedCrossRef

34.

Ormerod IE, Miller DH, McDonald WI, du Boulay EP, Rudge P, Kendall BE, Moseley IF, Johnson G, Tofts PS, Halliday AM et al (1987) The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quant study. Brain 110(Pt 6):1579–1616

35.

Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D (2011) Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol 258:2113–2127PubMedCrossRef

36.

Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW (2012) Evolution of MS lesions to black holes under DNA vaccine treatment. J Neurol 259:1375–1382PubMedCrossRef

37.

Pardini M, Bonzano L, Mancardi GL, Roccatagliata L (2010) Frontal networks play a role in fatigue perception in multiple sclerosis. Behav Neurosci 124:329–336PubMedCrossRef

38.

Patrucco L, Rojas JI, Cristiano E (2012) Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol 259:1317–1320PubMedCrossRef

39.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910PubMedCrossRef

40.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 69:292–302PubMedCrossRef

41.

Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691PubMedCrossRef

42.

Reilmann R, Holtbernd F, Bachmann R, Mohammadi S, Ringelstein EB, Deppe M (2012) Grasping multiple sclerosis: do quantitative motor assessments provide a link between structure and function? J Neurol. doi:10.1007/s00415-012-6639-7

43.

Riccitelli G, Rocca MA, Forn C, Colombo B, Comi G, Filippi M (2011) Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol 32:874–879PubMedCrossRef

44.

Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdova E, Hommes O, Lelorier J, Morrow SA, Oreja-Guevara C, Rijke N, Schippling S (2012) Future MS care: a consensus statement of the MS in the 21st Century Steering Group. J Neurol. doi:10.1007/s00415-012-6656-6

45.

Rocca MA, Absinta M, Filippi M (2012) The role of advanced magnetic resonance imaging techniques in primary progressive MS. J Neurol 259:611–621PubMedCrossRef

46.

Rocca MA, Agosta F, Colombo B, Mezzapesa DM, Falini A, Comi G, Filippi M (2007) fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp 28:373–382PubMedCrossRef

47.

Sepulcre J, Masdeu JC, Goni J, Arrondo G, Velez de Mendizabal N, Bejarano B, Villoslada P (2009) Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 15:337–344PubMedCrossRef

48.

Sicotte NL, Kern KC, Giesser BS, Arshanapalli A, Schultz A, Montag M, Wang H, Bookheimer SY (2008) Regional hippocampal atrophy in multiple sclerosis. Brain 131:1134–1141PubMedCrossRef

49.

Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65:268–275PubMedCrossRef

50.

Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P (2010) Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-anal approach. Neurol 75:302–309

51.

Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743–747PubMedCrossRef

52.

Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70:1150–1151PubMedCrossRef

53.

Yaldizli O, Glassl S, Sturm D, Papadopoulou A, Gass A, Tettenborn B, Putzki N (2011) Fatigue and progression of corpus callosum atrophy in multiple sclerosis. J Neurol 258:2199–2205PubMedCrossRef

54.

Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933PubMedCrossRef

55.

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M (2012) MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. doi:10.1002/ana.23676

Title: Multiple sclerosis imaging: recent advances
Authors: Maria A. Rocca
Roberta Messina
Massimo Filippi
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 3/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6788-8

2024 ASCO Annual Meeting

Springer Medicine

Multiple sclerosis imaging: recent advances

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network

Acknowledgement to Reviewers 2012

Pregnancy in congenital myasthenic syndrome

Effects of cerebellar infarcts on cortical processing of saccades

Ictal autoscopic phenomena and near death experiences: a study of five patients with ictal autoscopies

The neurological and ophthalmological manifestations of SPG4-related hereditary spastic paraplegia